Zim Laboratories Ltd

Zim Laboratories Ltd has announced that its Board of Directors will convene on November 4, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for both standalone and consolidated operations for the quarter ending September 30, 2026. In line with SEBI regulations, the company has also closed its trading window from October 1, 2026, to November 6, 2026, to prevent insider trading.

Zim Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 1st, 2026, and will reopen 48 hours after the declaration of the company's financial results for the quarter ending September 30th, 2026. This measure is standard practice to prevent insider trading during periods when material non-public information may be available.

Zim Laboratories Ltd has announced the incorporation of its wholly owned subsidiary, ZIM Laboratories SpA, in Santiago, Republic of Chile. This strategic move aims to expand and develop the company's pharmaceutical business within the LATAM region. The subsidiary was incorporated on September 9, 2026, with Zim Laboratories Ltd holding a 100% stake. The initial investment involved the subscription of 14,100 shares at a face value of CLP 1,000 each, with the consideration being cash.

Zim Laboratories Limited FZE, a wholly-owned subsidiary of Zim Laboratories Ltd, has successfully completed the investment of the entire approved amount in the share capital of its step-down subsidiary, ZIM Scientific Office L.L.C. The total investment amounts to AED 4,66,000 and AED 4,50,000, as previously disclosed. Following this investment, Zim Laboratories Limited FZE continues to hold 100% of the total share capital of ZIM Scientific Office L.L.C. This update confirms the finalization of the capital infusion into the subsidiary.

Zim Laboratories Ltd has released its Earnings Presentation for the first quarter of Fiscal Year 2027 (Q1 FY27). The presentation details financial performance, including Total Operating Income of ₹942 Mn, a decrease from ₹718 Mn in Q1 FY26. EBITDA stood at ₹34 Mn, down from ₹57 Mn in the prior year's quarter, resulting in a lower EBITDA margin of 3.7% compared to 7.9% in Q1 FY26. The company also reported a Total R&D Spend of ₹82 Mn, which included ₹34 Mn for BE studies and regulatory filings. The presentation covers business mix, R&D and innovation pipeline progress, and shareholding structure.

Zim Laboratories Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results during a meeting held on August 6, 2026. The results were prepared in accordance with Indian Accounting Standard 34 and reviewed by Deloitte Haskins & Sells LLP. The filing also lists the subsidiaries included in the consolidated results.

Zim Laboratories' consolidated Q1 FY27 revenue grew 31.2% YoY to ₹94.18 Cr (from ₹71.76 Cr), but the net loss widened to ₹4.02 Cr from ₹1.87 Cr a year ago, and the company swung from a ₹3.74 Cr profit in Q4 FY26 to this quarter's loss — QoQ revenue itself fell 10.5% from ₹105.27 Cr, consistent with a seasonally stronger Q4. Standalone mirrors the same story: revenue of ₹93.05 Cr against a loss that widened to ₹3.88 Cr from ₹1.69 Cr a year ago. No analyst consensus for this quarter could be located — web searches returned only results for the unrelated NYSE-listed shipping company that shares the ZIM ticker — so the print is assessed against management's own prior guidance rather than street estimates. At the Q4 FY26 concall, management had guided to "margin expansion in the mid-teens" for FY27 as EU GMP CAPA remediation completed and diversified markets scaled, while flagging near-term revenue drag from MENA geopolitical disruption and the EU GMP reinstatement process. This quarter runs counter to that framing on margins: consolidated OPM (EBITDA margin) compressed to 2.6% from 5.9% a year ago and 6.8% in Q4 FY26, even as gross margin (revenue less inventory-adjusted material costs) held roughly flat near 58%. The compression traces to "other expenses," which rose 44.6% YoY to ₹33.08 Cr — outpacing 31.2% revenue growth and rising from 31.9% to 35.1% of revenue — consistent with the compliance/logistics costs management flagged around EU GMP reinstatement and the MENA disruption. Employee costs (+31.3% YoY) and finance costs (+10.3% YoY) grew roughly in line with or slower than revenue and were not the primary drag. The quarter's other developments were largely administrative rather than operational catalysts: the board approved these unaudited results on 6 August, the company allotted 1,09,451 ESOP shares on 13 July, and promoter Dr Anwar Daud raised his stake by 0.15% on 16 June — none bearing directly on this quarter's cost pressure. No separate management press release accompanied the filing to contextualise the print beyond the financial statements. Going forward, the widening loss despite 31% YoY revenue growth means the mid-teens margin-expansion guidance is not yet visible in the numbers, keeping the EU GMP reinstatement timeline and the other-expenses trend as the key items to verify next quarter.

Zim Laboratories Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda for this meeting is to consider and approve the company's Unaudited Financial Results for the quarter ending June 30, 2026. These results will be presented on both a standalone and consolidated basis. Additionally, the company has informed about the closure of the trading window for its securities, effective from July 1, 2026, until August 8, 2026, in compliance with SEBI regulations regarding insider trading.

Zim Laboratories Ltd announced the allotment of 1,09,451 equity shares to eligible employees under the ZIM Laboratories Employee Stock Option Scheme (ESOS 2023). This allotment, approved via circular resolution on July 13, 2026, increases the company's paid-up equity share capital from Rs. 53,54,90,370 to Rs. 53,65,84,880. The new shares, with a face value of INR 10 each, were issued at an exercise price of INR 77.40 per share, realizing Rs. 84,71,507.40. The company confirmed these shares will rank pari-passu with existing equity shares.

Zim Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed effective from July 1, 2026, and will reopen 48 hours after the declaration of the company's financial results for the quarter ending June 30, 2026. This is a standard procedure to prevent potential insider trading during periods of sensitive financial information disclosure.